Heidelberg

• A study to Evaluate Efficacy and Safety of Giredestrant Compared with Fulvestrant (plus a CDK4/6 inhibitor), in Participants with ER+ HER2-N … Recruiting
  2022-502980-39-00 5 2024-01-25 Estrogen receptor (ER)-positive, HER2-negative advanced breast cancer
• Effect of acyclovir therapy on the outcome of ventilated patients with lower respiratory tract infection and detection of herpes simplex vir … Recruiting
  2023-504322-19-00 5 2024-01-10 Patients in the intensive care unit on ventilation with pneumonia and
• Randomized trial comparing efficacy and safety of initial triple therapy including parenteral treprostinil to initial double oral therapy in … Recruiting
  2023-504351-26-01 11 2023-12-06 Pulmonary arterial hypertension (group I)
• Long-term neuropsychologic outcome of pre-emptive mTOR inhibitor treatment in children with tuberous sclerosis complex (TSC) under 4 months … Recruiting
  2022-502332-39-00 4 2023-11-15 Tuberous sclerosis complex (TSC)
• Staphylococcus aureus Network Adaptive Platform trial (SNAP) Recruiting
  2023-503582-35-00 6 2023-10-26 Staphylococcus aureus bacteremia
• SGLT2 inhibition in addition to lifestyle intervention and risk for complications in subtypes of patients with prediabetes - a randomized, … Recruiting
  2024-512179-11-00 6 2023-10-26 Patients with prediabetes (defined as impaired fasting glucose [IFG] a
• Intensified treatment in patients with oligometastatic pancreatic cancer - multimodal surgical treatment versus systemic chemotherapy alone: … Recruiting
  2023-503558-10-00 5 2023-10-13 oligometastatic pancreatic cancer
• The Pancreatic Enzymes after Gastrectomy Trial Recruiting
  2022-501944-14-00 5 2023-10-02 Patients after gastrectomy (total and partial)
• Tebentafusp Regimen Versus Investigator’s Choice in Previously Treated Advanced Melanoma (TEBE-AM) Recruiting
  2022-502732-39-00 10 2023-09-01 Previously treated non-ocular advanced melanoma
• A Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Anti-Tumor Activity of IMA402, a Bispecific T Cell-Engag … Recruiting
  2022-503133-54-00 7 2023-08-09 Solid Tumors
• A multicentre, randomized trial in adults with de novo Philadelphia-Chromosome positive acute lymphoblastic leukemia to assess the efficacy … Recruiting
  2024-517966-40-00 4 2023-07-13 Acute lymphoblastic leukemia (ALL), de novo, Ph/BCR::ABL1 positive (Ph
• A Study of Subcutaneous Nivolumab + Relatlimab FDC in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY-127) Recruiting
  2022-500967-11-00 5 2023-07-06 Previously Untreated Metastatic or Unresectable Melanoma
• Combination treatment of Belantamab Mafodotin and Venetoclax in treatment of relapsed and refractory t(11;14) Multiple Myeloma (Phase I/IIa) … Recruiting
  2024-511794-30-00 9 2023-06-28 Multiple Myeloma
• Genomics guided targeted post-neoadjuvant therapy in patients with early breast cancer – a multicenter, open-label, umbrella phase-II study … Recruiting
  2024-514022-23-00 4 2023-06-23 Early breast cancer
• An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) Recruiting
  2022-502415-11-00 5 2023-06-16 Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
• Sotatercept in Children with Pulmonary Artery Hypertension on Standard of Care Recruiting
  2023-504861-22-00 4 2023-05-05 Pulmonary arterial hypertension
• The ACTION Study: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy Recruiting
  2022-502051-56-00 5 2023-04-28 H3 K27M-mutant diffuse glioma
• Phase 1 Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer Recruiting
  2023-504361-23-00 1 2023-03-30 Metastatic Castration-Resistant Prostate Cancer (mCRPC)
• A Phase 2/3 Randomized, Placebo-Controlled, Double-blind, Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vericigua … Recruiting
  2022-501238-52-00 10 2023-03-23 Heart failure due to systemic left ventricular systolic dysfunction
• A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF Class 1 and Class 2 alterations, in participan … Recruiting
  2024-513578-23-00 4 2023-03-21 Tumors harboring BRAF alterations
• International multicenter, open-label clinical trial for the treatment of acute myeloid leukemia in children and adolescents Recruiting
  2022-500783-35-00 5 2022-12-06 Acute Myeloid Leukemia
• A Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab-,Talquetamab- and JNJ-79635322-based Combination Regimens in Participants wit … Recruiting
  2024-517382-17-00 4 2022-11-30 Newly Diagnosed Multiple Myeloma in patients eligible for stem cell tr
• Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells Recruiting
  2023-507041-28-00 4 2022-11-28 Solid and Hematological Malignancies
• Renal Lifecycle Trial: A Randomized Controlled Clinical Trial to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in … Recruiting
  2023-508389-13-00 5 2022-11-08 Combined endpoint of all-cause mortality, kidney failure, and hospital

Showing 289–312 of 732 trials